Weiss, Geoffrey R.
Professor Emeritus, Medicine: Hematology and Oncology
- AB, Biology and Chemistry, Middlebury College, Middlebury, VT
- MD, Medicine, St. Louis University School of Medicine
- Internship, Internal Medicine, Temple University Hospital, Philadelphia, PA
- Residency, Internal Medicine, Temple University Hospital, Philadelphia, PA
- Chief Res, Internal Medicine, Temple University Hospital, Philadelphia, PA
- Clinical Fellowship, Medical Oncology, Dana Farber Cancer Center
New anticancer drug development, cancer immunotherapy
Geoffrey R. Weiss, M.D., is former chief of the Division of Hematology-Oncology and medical director of the Cancer Center, and professor of Medicine at UVA. A medical oncologist and clinical investigator, he was previously at the University of Texas Health Science Center at San Antonio, where he was an investigator for the Institute for Drug Development; during that time he contributed to the clinical advance of 40 new anticancer agents. Dr. Weiss has devoted much of his investigational career to the development of new therapies for genitourinary malignancies and for malignant melanoma.Since 1986 he has been a member of the Cytokine Working Group, a multi-institution clinical research consortium dedicated to the evaluation of cytokine-based therapies of renal cell carcinoma and malignant melanoma; this group has been central to the development of high-dose nterleukin-2 as an FDA-approved therapy of renal cell carcinoma and malignant melanoma.
Dr. Weiss joined the UVA Cancer Center in November 2004, where he has been a co-investigator in clinical trials for synthetic peptide vaccines for malignant melanoma. At UVA he also launched a clinical program utilizing high-dose interleukin-2 for the treatment of renal cell carcinoma and malignant melanoma.